Showing 2684 results
-
Press Release /EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and…
-
Press Release /If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-…
-
Press Release /Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively…
-
Press Release /Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for…
-
Press Release /
Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case
Sandoz evaluating next steps, including potential appeal to US Supreme Court Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic… -
Press Release /European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with…
-
Key Release /Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related…
-
Press Release /Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19…
-
Press Release /Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) was superior to once-daily IND/MF (QMF149) in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care…
-
Key Release /En raison du Covid-19 les résultats du S1 sont plus représentatifs de la performance sous-jacente que ceux du T2, croissance de 6% (tcc1, +3% USD) du chiffre d’affaires et de 19% (tcc, +14% USD) du…